Skip to main content

TNF inhibitor

Shingles Risk with JAK Inhibitors and Other Biologics

Jul 29, 2021

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.



RA patients from the German RABBIT register were prospectively enrolled (2007 - 2020)

Read Article

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

Jul 29, 2021

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Read Article

Cardiovascular Prevention Lacking in Rheumatoid Arthritis

Jul 28, 2021

An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).

Read Article

DMARD Effects on COVID-19 Outcomes

Jul 26, 2021

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (

Read Article

Tofacitinib Efficacy in Ankylosing Spondylitis

Jul 22, 2021

Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and is safe. 

Read Article
Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7

Dr. John Cush @RheumNow( View Tweet )

Jul 21, 2021
Study of 33 RCTs, 4544 pts Rx w/ either IL-17 or TNF inhibitors finds lower risk of UVEITIS with anti-TNF mAb (vs PBO OR = 0.46; vs IL-17i OR = 0.34. IL-17 inhibitors are not protective against uveitis https://t.co/AIxgI2qhq9

Dr. John Cush @RheumNow( View Tweet )

Jul 19, 2021
Rheums--Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/kKoBTHWX6z
Dr. John Cush @RheumNow( View Tweet )
Jul 17, 2021

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Jul 09, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ICYMI: Psoriatic Disease Management - RNL 2021 Highlights

Jul 08, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article

ICYMI: Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Jul 05, 2021

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to at-

Read Article

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jul 05, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article
Download this week’s podcast titled “Good as I Ever Was”. You can find us on SoundCloud and wherever you download your podcasts. https://t.co/hVMf8X5Dx3 https://t.co/uUDCXzO2eU
Dr. John Cush @RheumNow( View Tweet )
Jul 04, 2021

ACR Stands Against Insurer Mandated Infusion Locations

ACR
Jun 28, 2021

The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a

Read Article
The Swedish Rheumatology Quality Register looked at risk of ant.uveitis (AU). From 4851 starting secukinumab (456) or TNFinhibitor (4395 ), there was higher AU risk w/ SEC (adj HR 2.32; 1.16-4.63) & ETN (1.82;1.13-2.93) (ADA as referent) https://t.co/j06MtKedYU

Dr. John Cush @RheumNow( View Tweet )

Jun 25, 2021

Better Outcomes with Modern T2T in Pregnancy

Jun 23, 2021

With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.

Read Article

Progression from Psoriasis to Psoriatic Arthritis

Jun 22, 2021

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).



A retrospecitve analysis of non-randomized moderate-

Read Article

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age, gender, comorbidities, line of therapy and access to treatment, you may find highly variable

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article

How do we personalize psoriatic arthritis treatment?

Jun 07, 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?



Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

Read Article
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 05, 2021
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 05, 2021
×